We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop NAT Diagnostic System

By HospiMedica staff writers
Posted on 13 May 2002
An agreement to develop and distribute a customized integrated diagnostic system for use in nucleic acid sample preparation, detection, and quantification of the hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV-1 has been announced by Roche Molecular Systems (Pleasanton, CA, USA) and Qiagen GmbH (Venlo, The Netherlands). More...
The system will be based on the polymerase chain reaction (PCR) technology of Roche.

The customized system will incorporate modified versions of automated sample preparation modules from Qiagen, called TaqPrep. TaqPrep will be integrated with a modified version of Roche's TaqMan Analyzer, designed to target amplification using real-time PCR and nucleic acid extraction methods for the detection of viruses. These integrated systems will be distributed by Roche to large US reference laboratories.

Using Qiagen's proprietary silica membrane technologies, extraction of both DNA and RNA can be performed on a fully automated basis, processing 96 samples in only a few hours. With Roche's technology, amplification and detection of nucleic acid occurs simultaneously in a single reaction tube and can be monitored in real-time, allowing for more rapid and reliable detection, says Roche. Specially designed hardware and software will be utilized for positive sample tracking, integrating the entire testing process for laboratories, with a turn-around time of less than six hours.

"Qiagen's technology and market leadership in nucleic acid purification in molecular diagnostics is adding substantial value to the development of standardized and highly efficient solutions in this emerging and rapidly growing market,” said Dr. Helge Bastian, vice president, global strategic marketing at Qiagen.



Related Links:
Roche Molecular Systems
Qiagen

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Automatic CLIA Analyzer
Shine i6000
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.